Parkinson disease: Proteomic tools identify dementia biomarkers in PD


Patients with Parkinson disease (PD) have around a 30% risk of developing dementia. PD dementia (PDD) is currently diagnosed on the basis of clinical and neurophysiological tests, but laboratory biomarkers will be needed if the diagnosis and treatment of this condition are to be further improved. Stefan Lehnert, Markus Otto and colleagues have attempted to address this need by using a mass spectrometry-based proteomic strategy—iTRAQ and multiple reaction monitoring (MRM)—to identify candidate cerebrospinal fluid (CSF) biomarkers for PDD. “In recent years, the workhorse in proteomic research has been twodimensional difference gel electrophoresis technology,” says Otto. “However, the findings have rarely made their way into routine diagnostics, partly due to the fact that most brain-specific proteins have so far eluded identification.” The authors explain that brain-derived proteins tend to be present at low concentrations in the CSF compared with blood-derived proteins, so the molecules of interest can often be difficult to detect. iTRAQ is a gel-free proteomic technique that enables peptides to be both identified and quantified in a single experiment. The researchers chose MRM as their validation method because, unlike moreconventional approaches, it does not rely on the availability of antibodies for peptide quantification. “An infinite number of peptides or proteins can be detected in PARKINSON DISEASE

DOI: 10.1038/nrneurol.2012.34

Cite this paper

@article{Wood2012ParkinsonDP, title={Parkinson disease: Proteomic tools identify dementia biomarkers in PD}, author={Heather D Wood}, journal={Nature Reviews Neurology}, year={2012}, volume={8}, pages={180-180} }